drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Autologous/allogeneic T cells transduced with a lentiviral vector encoding a CD33-specific CAR; IV infusion with dose escalation; targets CD33+ myeloid blasts in AML and related myeloid malignancies.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous/allogeneic T cells are lentivirally engineered to express a CD33‑specific chimeric antigen receptor. The CAR enables MHC‑independent recognition of CD33 on myeloid blasts, triggering T‑cell activation and expansion, release of perforin/granzymes and inflammatory cytokines, and subsequent cytotoxic clearance of CD33+ AML and related myeloid malignancy cells.
drug_name
CD33-directed CAR T cells
nct_id_drug_ref
NCT06849921